Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
2B3-101 in solid tumors with brain metastases or recurrent malignant glioma
NL-OMON26600Phase 1Recruiting
- Sponsor
- 2-BBB Therapeutics
- Start
- Jul 2011
- Modality
- Small Molecules, Liposomes → Lipid-based Nanoparticles → Nanoparticles → Drug Delivery Systems
- Countries
- 1
01
Overview
Phase 1, open-label trial of doxorubicin glutathione pegylated liposomal in Nonhematologic neoplasms, malignant glioma and breast cancer (2 arms), sponsored by 2-BBB Therapeutics. Primary endpoint: Safety and tolerability. Started Jul 2011; status: recruiting.
02
Drugs
doxorubicin glutathione pegylated liposomal
03
Conditions
Nonhematologic neoplasmsmalignant gliomabreast cancer
Beyond the preview
Go deeper on NL-OMON26600.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON26600.